Producing safe, effective, high-quality viral vector therapeutics depends on a robust and tailored analytical testing strategy.

Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in viral ...

Dr Reddy’s Laboratories' subsidiary, Aurigene Oncology Limited, received DCGI approval to conduct a phase-2 trial for India's ...

A number of recent clinical trials have suggested that gene therapy could help treat diseases of the eye that cause vision ...

Joshua Cruce brings over a decade of strategic expertise to lead Vector Risk Solutions' growth, ensuring innovation, ...

We recommend a Hold on Benitec Biopharma due to speculative nature and early-stage progress, but worth watching for potential ...

Aurigene announces phase 1 study for India’s first trial for novel autologous CAR-T cell therapy for multiple myeloma: Our Bureau, Bengaluru Wednesday, October 9, 2024, 16:45 Hr ...

Transgene will present median 24-month follow up data from patients enrolled in the Phase I trial evaluating the individualized cancer vaccine ...

D stock is a contrarian trade opportunity based on the market assumption that the promising Wet Amd eye disease gene therapy ...

Nouscom has also exclusively out-licensed VAC-85135, an off-the-shelf immunotherapy developed under a multi-project agreement, which is currently under evaluation in a Phase 1 trial for the treatment ...

Dr Reddy's Laboratories' subsidiary, Aurigene Oncology, has been authorized by the DCGI to initiate phase-2 trials for Ribrecabtagene autoleucel, a novel CAR-T cell therapy targeting multiple myeloma, ...

Aurigene Oncology, a wholly-owned subsidiary of Dr. Reddy's Laboratories has announced the Phase 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study - India's first trial for a ...